If you wish to increase the text size of this publication, maximize your window.
Click outside the box below, press Ctrl “+” several times, then scroll.
Questions? Email: [email protected] 

- Varley, Christopher K. Overview of DSM-5 Changes. Seattle Childrens, New York State Office of Mental Health, p. 30-33.
Reviewed 2023

Update
Rituximab as an adjunctive treatment for schizophrenia spectrum disorder
or obsessive-compulsive disorder:
Two open-label pilot studies on treatment-resistant patients

- Bejerot, S., Sigra Stein, S., Welin, E., Eklund, D., Hylén, U., & Humble, M. B. (2023). Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: Two open-label pilot studies on treatment-resistant patients. Journal of psychiatric research, 158, 319–329. https://doi.org/10.1016/j.jpsychires.2022.12.003

Peer-Reviewed Journal Article References:
Kamath, V., Crawford, J., DuBois, S., Nucifora, F. C., Jr., Nestadt, G., Sawa, A., & Schretlen, D. (2019). Contributions of olfactory and neuropsychological assessment to the diagnosis of first-episode schizophrenia. Neuropsychology, 33(2), 203–211.

Lopez, D., & Weisman de Mamani, A. (2020). Family-related risk and protective factors for suicidal ideation in individuals with schizophrenia spectrum disorders. Professional Psychology: Research and Practice. Advance online publication.

Penney, D., El-Baalbaki, G., & Lepage, M. (2021). Exploring the factor structure of the PTSD checklist for DSM–5 in psychotic disorders. Psychological Trauma: Theory, Research, Practice, and Policy. Advance online publication.

QUESTION 4
What are the positive symptoms an individual must have for a diagnosis of schizophrenia in DSM-5? To select and enter your answer go to Test.